Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken
An Erratum on
Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken
by Liedtke, W. (2022). Front. Mol. Neurosci. 15:865600. doi: 10.3389/fnmol.2022.865600
Due to a production error, the “Conflict of Interest” statement incorrectly stated that “WL was a full-time” instead of “WL is a full-time.”
The corrected section should read:
“WL is a full-time executive employee of Regeneron Pharmaceuticals, Tarrytown, NY, United States.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: pain, spinal cord dorsal horn, KCC2, Kcc2 gene expression enhancer, GSK3, delta-catenin, Kaiso
Citation: Frontiers Production Office (2022) Erratum: Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken. Front. Mol. Neurosci. 15:979385. doi: 10.3389/fnmol.2022.979385
Received: 27 June 2022; Accepted: 27 June 2022;
Published: 05 July 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org